Pharma的新Bcl-2抑制剂Lisaftoclax获得中国血液癌治疗优先审查。 Ascentage Pharma's new Bcl-2 inhibitor, Lisaftoclax, gains Priority Review in China for treating blood cancers.

亚盛药业的新型Bcl-2抑制剂Lisaftoclax已被接受在中国进行优先审查,用于治疗复发性或耐药性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤. Ascentage Pharma's novel Bcl-2 inhibitor, Lisaftoclax, has been accepted for Priority Review in China for treating relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. 这是中国国内开发的第一种Bcl-2抑制剂,如果得到批准,可以是全球核准的第二种此类药物。 This is China's first domestically developed Bcl-2 inhibitor and, if approved, could be the second such drug approved globally. 该药物正在各种癌症的多种第三阶段研究中进行测试。 The drug is being tested in multiple phase III studies for various cancers.

文章

PR Newswire

The Manila Times

LeLézard

-- 显示更少 --

延伸阅读

相关故事